Atyr Pharma Inc Dossier - Source-backed chat

Atyr Pharma Inc

ATYRNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.69

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.30Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $29.7M

Enterprise Value $14.3M

Shares Outstanding 102.7M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

aTyr Pharma is a clinical-stage biotechnology company transitioning its lead candidate, efzofitimod, into a redesigned clinical path. Following the Phase 3 EFZO-FIT trial's failure to meet its primary steroid-sparing endpoint in pulmonary sarcoidosis, the company has pivoted. After a Type C meeting with the FDA, aTyr plans to launch a new global Phase 3 trial targeting forced vital capacity (FVC) in restrictive patients with a more frequent dosing regimen (every three weeks). While the company maintains a solid cash runway of $68.3 million (as of March 31, 2026) to fund near-term operations, the clinical setback has significantly increased the risk profile and delayed commercialization timelines. Additionally, the termination of the Japanese partnership with Kyorin returns global rights to aTyr but removes near-term milestone payments. A 'Hold' rating is recommended as the market waits for execution on the new Phase 3 trial design and enrollment progress in the Phase 2 SSc-ILD trial.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$2.86

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The IND submission for the redesigned Phase 3 trial is delayed, or the FDA requests additional preclinical/clinical safety data regarding anti-synthetase syndrome. The Phase 2 SSc-ILD trial fails to show clinical benefit, leaving the company with a single, highly risky clinical asset. Rapid cash burn forces highly dilutive equity financing at depressed share prices, and failure to regain Nasdaq compliance leads to delisting to OTC markets.

Base CaseCentral scenario

The company successfully files the IND in June 2026 and initiates the redesigned Phase 3 trial in pulmonary sarcoidosis. Enrollment for the Phase 2 EFZO-CONNECT trial in SSc-ILD completes, providing a secondary clinical catalyst. Cash reserves of $68.3 million sustain operations into mid-2027, but the company will eventually need to raise dilutive capital or secure a new global partner to fund the late-stage pipeline. Nasdaq compliance is maintained, potentially via a reverse stock split.

Bull CaseUpside scenario

The bull case centers on the Phase 3 ATHIRA trial readout for lead candidate efzofitimod in pulmonary sarcoidosis. If successful, efzofitimod would become the first novel-mechanism sarcoidosis therapy in decades, addressing a multi-billion-dollar uncontested market with potential for blockbuster revenue ($1B+ annually). Additionally, the company's proprietary tRNA synthetase (Physiocrine) platform provides a differentiated biological mechanism (neuropilin-2 modulation) and a robust pipeline beyond its lead program.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clear regulatory path forward established with the FDA for a redesigned Phase 3 trial in pulmonary sarcoidosis using FVC as the primary endpoint.
Reversion of Japanese rights from Kyorin provides aTyr with full global commercial control of efzofitimod.
Solid near-term cash position of $68.3 million as of March 31, 2026, providing at least a one-year runway.
Differentiated mechanism of action targeting Neuropilin-2 (NRP2) to resolve chronic inflammation and fibrosis without broad immunosuppression.

Key Investment Risks

High clinical development risk following the failure of the previous Phase 3 EFZO-FIT trial to meet its primary endpoint.
No current product revenue and reliance on capital markets or partnerships for long-term funding.
Nasdaq delisting risk due to minimum bid price deficiency, with a compliance deadline of November 30, 2026.
Loss of non-dilutive milestone funding following the termination of the Kyorin collaboration.

Thesis Invalidation Triggers

FDA refusal or significant delay in clearing the IND for the redesigned Phase 3 pulmonary sarcoidosis trial.
Failure of the Phase 2 EFZO-CONNECT trial in SSc-ILD to meet its primary safety or efficacy endpoints.
Cash runway dropping below 6 months without a clear financing or partnership strategy.
Inability to regain compliance with Nasdaq's minimum bid price requirement, resulting in delisting.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.